Table 2.

Relationship Between Karnofsky Performance Status and Clinical Outcomes of Patients Listed for SLKT (Cohort 1)

	Unadjusted HR	Adjusted HR*	Unadjusted SHR	Adjusted SHR*
Death/deterioration
Karnofsky A	1 (Ref)	1 (Ref)	1 (Ref)	1 (Ref)
Karnofsky B	1.36 (1.25–1.49)	1.16 (1.05–1.27)	1.06 (0.97–1.15)	1.06 (0.971.16)
Karnofsky C	2.93 (2.67–3.23)	1.49 (1.34–1.66)	1.32 (1.21–1.45)	1.15 (1.041.28)
Transplantation
Karnofsky A	1 (Ref)	1 (Ref)	1 (Ref)	1 (Ref)
Karnofsky B	1.30 (1.21–1.40)	1.04 (0.97–1.13)	1.14 (1.06–1.22)	0.98 (0.911.05)
Karnofsky C	2.51 (2.33–2.71)	1.30 (1.19–1.42)	1.56 (1.45–1.67)	1.06 (0.971.15)
Death or transplantation
Karnofsky A	1 (Ref)	1 (Ref)	N/A	N/A
Karnofsky B	1.33 (1.25–1.40)	1.09 (1.03–1.16)
Karnofsky C	2.67 (2.52–2.84)	1.38 (1.29–1.47)

^*Adjusted for Age, Sex, Race/Ethnicity, Diabetes, MELD, Albumin, Dialysis, ABO Blood type, Ascites, Encephalopathy, Cirrhosis Etiology, HCC, Region, Year of Listing